Research Reveals Cystic Fibrosis Severity Is Linked to Fungus

Since current treatments for MABSC are rather limited in effectiveness and they present severe unwanted side effects, AIT’s new generator and delivery system aims to provide medical advantages to patients with no additional concerns relating to safety. “Our in-vitro data provide valuable confirmation of the direct killing power of NO. With our NO generator and delivery system successfully used in a real-world setting, we are well on our way to effectively treat patients in their homes for chronic, severe, refractory bacterial lung infections,” said Steven Lisi, chairman and CEO of AIT Therapeutics.

References

https://cysticfibrosisnewstoday.com/2018/05/30/disease-severity-cystic-fibrosis-linked-immune-overreaction-fungus-study/

https://cysticfibrosisnewstoday.com/2018/06/29/ait-therapeutics-presenting-nitric-oxide-data-upcoming-conference/

https://globenewswire.com/news-release/2018/06/27/1530638/0/en/AIT-Therapeutics-Announces-Human-and-In-Vitro-Nitric-Oxide-Data-to-be-Presented-at-the-3rd-Annual-World-Bronchiectasis-Conference.html

https://cysticfibrosisnewstoday.com/nitric-oxide-inhaled-for-lung-infections/

https://cysticfibrosisnewstoday.com/2016/11/15/multi-drug-resistant-bacterium-speading-among-cystic-fibrosis-patients-study-warns/

https://cysticfibrosisnewstoday.com/2017/12/01/phase-2-trial-shows-aits-nitric-oxide-therapy-helps-cf-patients-with-infections-breathe-better/